Browsing by Author Tanwandee, T

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 10 to 21 of 21 < previous 
TitleAuthor(s)Issue DateViews
 
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine
Journal:Clinical Gastroenterology and Hepatology
Park, JLe, AKTseng, TCYeh, MLJun, DWTrinh, HWong, GLHCheng, CHPeng, CYKim, SEOh, HKwak, MSCheung, KSMToyoda, HHsu, YCJeong, JYYoon, ELUngtrakul, TZhang, JXie, QAhn, SBEnomoto, MShim, JJCunningham, CJeong, SWCho, YKOgawa, EHuang, RLee, DHTakahashi, HTsai, PCHuang, CFDai, CYTseng, CHYasuda, SKozuka, RLi, JWong, CWong, CCZhao, CHoang, JEguchi, YWu, CTanaka, YGane, ETanwandee, TCheung, RYuen, RMFLee, HSYu, MLKao, JHYang, HINguyen, MH
2021
14
 
A randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results
Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2013
Kudo, MFinn, RPoon, RTPBlanc, JFHan, GYan, LYang, JLu, LTak, WYXU, XLee, JHLin, SMWu, CTanwandee, TShao, GWalters, LDela Cruz, CPoulart, VWang, JH
2013
42
 
Real-world rates of hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB): a systematic review, conventional aggregated data meta-analysis (ADMA) and individual patient data meta-analysis (IPDMA)
Proceeding/Conference:Gastroenterology
Yeo, YHHo, HJYang, HITseng, TCKwak, M-SPark, YMFung, JYYButi, MRodriguez, MTreeprsertsuk, SPreda, CMUngtrakul, TCharatcharoenwithaya, PLi, XLe, MHWei, BZou, BLe, AKJeong, DChien, NKam, LHosaka, TRiveiro, MProca, DSuzuki, FKobayashi, MSriprayoon, TChong, YTanwandee, TYuen, RMFLee, H-SKao, J-HLok, AWu, C-YNguyen, MH
2018
28
 
Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy
Proceeding/Conference:Journal of Hepatology
Zhou, XKazma, RMeinel, DZhou, YYuen, RMFGane, ESchwabe, CTanwandee, TCao, LZhou, JBo, Q
2020
28
 
Results of TRACER: a phase II randomized, double-blinded, multicenter Asian study investigating the combination of transcatheter arterial chemoembolization (TACE) and oral everolimus in localised unresectable hepatocellular carcinoma (HCC)
Proceeding/Conference:Liver Cancer
Sukeepaisarnjaroen, WLin, SMLu, SNPaik, SWTanwandee, TLee, HCChen, SCYau, TCCKomolmit, PMa, CSuryavanshi, MXue, HSlader, CPoon, RTP
2016
64
 
RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients
Proceeding/Conference:Journal of Hepatology
Gane, EYuen, RMFBo, QYSchwabe, .CTanwandee, TDas, SJin, YYGuo, LZhou, XWang, YFFeng, SMeinel, DZhu, MF
2019
37
 
RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy
Proceeding/Conference:Journal of Hepatology
Yuen, RMFGane, EKim, DJChan, HSurujbally, BPavlovic, VTriyatni, MGrippo, JKim, HJLeerapun, ALim, THLim, YSTanwandee, TKim, WCheng, WHu, THWat, C
2020
49
 
Sa1483 - Real-World Rates of Hepatitis B Surface Antigen (HBSAG) Seroclearance in Patients with Chronic Hepatitis B (CHB): A Systematic Review, Conventional Aggregated Data Meta-Analysis (ADMA) and Individual Patient Data Meta-Analysis (IPDMA)
Proceeding/Conference:Gastroenterology
Yeo, YHHo, HJYang, HITseng, TCKwak, MSPark, YMFung, JYYButi, MRodriguez, MTreeprasertsuk, SPreda, CMUngtrakul, TCharatcharoenwitthaya, PLi, XYLe, MHWei, BZou, BYLe, AKJeong, DChien, NKam, LHosakh, TRivetro, MProca, DSuzuki, FKobayashi, MSriprayoon, TChong, YTanwandee, TYuen, RMFLee, HSKao, JHLok, AWu, CYNguyen, MH
2018
67
 
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, RMFZhou, XGane, ESchwabe, CTanwandee, TFeng, SJin, YYTriyatni, MLemenuel-Diot, ACosson, VXue, ZHKazma, RBo, QY
2021
 
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B
Journal:Hepatology Communications
Yuen, MFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, YSKim, YJPoovorawan, KTangkijvanich, PSchwabe, CEley, TBrown, JLee, ACHThi, EPParatala, BMani, NSofia, MJPicchio, GSims, KDGane, EJ
4-Oct-2022
 
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB-506 in healthy subjects (HS) and chronic hepatitis B (CHB) subjects
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, Y-SKim, YJPoovorawan, KTangkijvanich, PChan, HLYEley, TBrown, JMoore, CLee, ACHKim, JThi, EPMani, NRijnbrand, RCole, ASofia, MJPicchio, GRSims, KGane, EJ
2019
48
 
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
Journal:Hepatology International
Liu, MTseng, TCJun, DWYeh, MLTrinh, HWong, GLHChen, CHPeng, CYKim, SEOh, HKwak, MSCheung, MToyoda, HHsu, YCJeong, JYYoon, ELUngtrakul, TZhang, JXie, QAhn, SBEnomoto, MShim, JJCunningham, CJeong, SWCho, YKOgawa, EHuang, RLee, DHTakahashi, HTsai, PCHuang, CFDai, CYTseng, CHYasuda, SKozuka, RLi, JWong, CWong, CCZhao, CHoang, JEguchi, YWu, CTanaka, YGane, ETanwandee, TCheung, RYuen, MFLee, HSYu, MLKao, JHYang, HINguyen, MH
2021
11
Showing results 10 to 21 of 21 < previous